Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Patent (484) 484
Journal Article (193) 193
Publication (33) 33
Newspaper Article (14) 14
Book / eBook (3) 3
Book Chapter (3) 3
Conference Proceeding (3) 3
Book Review (2) 2
Magazine Article (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
chemistry (473) 473
metallurgy (471) 471
organic chemistry (470) 470
human necessities (462) 462
hygiene (462) 462
medical or veterinary science (462) 462
peptides (459) 459
preparations for medical, dental, or toilet purposes (459) 459
specific therapeutic activity of chemical compounds ormedicinal preparations (294) 294
microbiology (179) 179
biochemistry (172) 172
beer (171) 171
enzymology (171) 171
mutation or genetic engineering (171) 171
spirits (171) 171
vinegar (171) 171
wine (171) 171
compositions thereof (169) 169
culture media (169) 169
microorganisms or enzymes (169) 169
propagating, preserving or maintaining microorganisms (169) 169
general tagging of cross-sectional technologies spanning over several sections of the ipc (165) 165
general tagging of new technological developments (165) 165
technical subjects covered by former uspc cross-reference art collections [xracs] and digests (165) 165
technologies for adaptation to climate change (165) 165
technologies or applications for mitigation or adaptation againstclimate change (165) 165
investigating or analysing materials by determining theirchemical or physical properties (100) 100
measuring (100) 100
physics (100) 100
testing (100) 100
humans (91) 91
index medicus (71) 71
fermentation or enzyme-using processes to synthesise a desiredchemical compound or composition or to separate optical isomersfrom a racemic mixture (68) 68
agriculture (59) 59
animal husbandry (59) 59
care of birds, fishes, insects (59) 59
fishing (59) 59
forestry (59) 59
hunting (59) 59
new breeds of animals (59) 59
rearing or breeding animals, not otherwise provided for (59) 59
trapping (59) 59
compositions or test papers therefor (44) 44
condition-responsive control in microbiological orenzymological processes (44) 44
measuring or testing processes involving enzymes, nucleicacids or microorganisms (44) 44
processes of preparing such compositions (44) 44
immunotherapy (41) 41
animals (40) 40
female (40) 40
immunology (39) 39
nucleotides (38) 38
derivatives thereof (36) 36
male (36) 36
nucleic acids (36) 36
nucleosides (36) 36
sugars (36) 36
cancer (35) 35
mice (32) 32
oncology (30) 30
adult (25) 25
melanoma (25) 25
dermatology (23) 23
middle aged (23) 23
antibodies, monoclonal - therapeutic use (20) 20
aged (19) 19
ipilimumab (19) 19
tumors (19) 19
care and treatment (17) 17
pd-1 (17) 17
psoriasis (17) 17
metastatic melanoma (16) 16
regulatory t-cells (16) 16
therapy (16) 16
antigens (15) 15
cell line, tumor (15) 15
article (14) 14
research (14) 14
drug therapy (13) 13
expression (13) 13
life sciences (13) 13
multidisciplinary sciences (13) 13
abridged index medicus (12) 12
ctla-4 (12) 12
ctla-4 blockade (12) 12
lymphocytes (12) 12
mice, inbred c57bl (12) 12
treatment outcome (12) 12
antibodies (11) 11
antibodies, monoclonal - immunology (11) 11
cell biology (11) 11
ligands (11) 11
programmed cell death 1 receptor - antagonists & inhibitors (11) 11
t cells (11) 11
antibodies, monoclonal - pharmacology (10) 10
dendritic cells (10) 10
immune response (10) 10
lymphocytes t (10) 10
monoclonal antibodies (10) 10
neoplasms - immunology (10) 10
prospective studies (10) 10
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (622) 622
French (124) 124
German (55) 55
Spanish (47) 47
Chinese (33) 33
Portuguese (18) 18
Korean (17) 17
Danish (8) 8
Norwegian (7) 7
Slovenian (7) 7
Japanese (6) 6
Greek (5) 5
Croatian (4) 4
Russian (4) 4
Polish (3) 3
Hungarian (2) 2
Italian (1) 1
Lithuanian (1) 1
Serbian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Blood-brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy
by Galstyan, A and Markman, JL and Shatalova, ES and Chiechi, A and Korman, AJ and Patil, R and Klymyshyn, D and Tourtellotte, WG and Israel, LL and Braubach, O and Ljubimov, VA and Mashouf, LA and Ramesh, A and Grodzinski, ZB and Penichet, ML and Black, KL and Holler, E and Sun, T and Ding, H and Ljubimov, AV and Ljubimova, JY
NATURE COMMUNICATIONS, ISSN 2041-1723, 08/2019, Volume 10, Issue 1, pp. 3850 - 13
Brain glioma treatment with checkpoint inhibitor antibodies to cytotoxic T-lymphocyte-associated antigen 4 (a-CTLA-4) and programmed cell death-1 (a-PD-1) was... 
SYSTEM | INTERLEUKIN-2 | PROTEIN | IMMUNOTHERAPY | MACROPHAGES | MULTIDISCIPLINARY SCIENCES | BLOCKADE | IDENTIFICATION | GLIOBLASTOMA ERADICATION | ANAPHYLAXIS | DELIVERY | Brain | PD-1 protein | CD8 antigen | Brain tumors | Brain cancer | Glioblastoma | Antibodies | Cytotoxicity | Activation | Lymphocytes T | Macrophages | Biopolymers | Blood | Bearing | CTLA-4 protein | Blood-brain barrier | Lymphocytes | Malic acid | Movement disorders | Immune system | Antigens | Cell survival | Immune response | Immunoregulation | Inhibitors | Immune checkpoint | Immunoconjugates | Glioma | Cell death | Mice | Tumors | Apoptosis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text An open-label, multiple ascending dose study of the anti-CTLA-4 antibody ipilimumab in viremic HIV patients
by Colston, Elizabeth and Grasela, Dennis and Gardiner, David and Bucy, R. Pat and Vakkalagadda, Blisse and Korman, Alan J and Lowy, Israel
PLoS ONE, ISSN 1932-6203, 06/2018, Volume 13, Issue 6, pp. e0198158 - e0198158
Expression of cytotoxic T-lymphocyte antigen 4 (CTLA-4), a negative regulator of T-cell function, is increased in chronic HIV-1 infection. It was hypothesized... 
TRIAL | METASTATIC MELANOMA | INFLAMMATION | MULTIDISCIPLINARY SCIENCES | IMMUNE ACTIVATION | ANTIRETROVIRAL THERAPY | CTLA-4 | INFECTION | T-CELL EXHAUSTION | UP-REGULATION | EXPRESSION | HIV Infections - virology | Humans | Middle Aged | Male | RNA, Viral - blood | CD4 Lymphocyte Count | Ipilimumab - adverse effects | Viremia - drug therapy | CTLA-4 Antigen - immunology | Dose-Response Relationship, Drug | HIV Infections - immunology | HIV-1 - immunology | Maximum Tolerated Dose | Adult | Female | HIV Infections - drug therapy | Viremia - immunology | CTLA-4 Antigen - antagonists & inhibitors | Ipilimumab - administration & dosage | Viremia - metabolism | HIV Infections - metabolism | Ipilimumab - pharmacokinetics | Safety and security measures | Immune response | Ipilimumab | HIV patients | Dosage and administration | Research | Drug therapy | Pharmacokinetics | Health aspects | HIV infection | Corticoids | Toxicity | Viremia | CD8 antigen | Chronic infection | Clinical trials | Cytotoxicity | Infections | Lymphocytes T | Metastasis | Hepatitis | CTLA-4 protein | Acquired immune deficiency syndrome--AIDS | Lymphocytes | Antiretroviral agents | Human immunodeficiency virus--HIV | Paralysis | Drug dosages | Antinuclear antibodies | Chronic illnesses | Immune system | Antigens | Corticosteroids | Research & development--R&D | Melanoma | Diarrhea | Pharmacology | Ribonucleic acid--RNA | Patients | Antiretroviral therapy | CD4 antigen | Viability | Viral infections | Index Medicus | RNA | Research & development | Acquired immune deficiency syndrome | Ribonucleic acid | AIDS | R&D | HIV | Human immunodeficiency virus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Nivolumab and urelumab enhance antitumor activity of human T lymphocytes engrafted in Rag2-/-IL2Rγnull immunodeficient mice
by Sanmamed, Miguel F and Rodriguez, Inmaculada and Schalper, Kurt A and Oñate, Carmen and Azpilikueta, Arantza and Rodriguez-Ruiz, Maria E and Morales-Kastresana, Aizea and Labiano, Sara and Pérez-Gracia, Jose L and Martín-Algarra, Salvador and Alfaro, Carlos and Mazzolini, Guillermo and Sarno, Francesca and Hidalgo, Manuel and Korman, Alan J and Jure-Kunkel, Maria and Melero, Ignacio
Cancer Research, ISSN 0008-5472, 09/2015, Volume 75, Issue 17, pp. 3466 - 3478
A current pressing need in cancer immunology is the development of preclinical model systems that are immunocompetent for the study of human tumors. Here, we... 
DNA-Binding Proteins - immunology | Humans | Tumor Necrosis Factor Receptor Superfamily, Member 9 - immunology | Programmed Cell Death 1 Receptor - antagonists & inhibitors | DNA-Binding Proteins - genetics | Graft vs Host Disease - immunology | Interleukin Receptor Common gamma Subunit - genetics | Interleukin Receptor Common gamma Subunit - immunology | Graft vs Host Disease - pathology | HT29 Cells | Lymphocyte Activation - immunology | Animals | Colorectal Neoplasms - immunology | Antibodies, Monoclonal - administration & dosage | T-Lymphocytes - drug effects | Tumor Necrosis Factor Receptor Superfamily, Member 9 - antagonists & inhibitors | Colorectal Neoplasms - drug therapy | Leukocytes, Mononuclear - immunology | Programmed Cell Death 1 Receptor - biosynthesis | Mice | Programmed Cell Death 1 Receptor - immunology | T-Lymphocytes - pathology | Colorectal Neoplasms - pathology | Tumor Necrosis Factor Receptor Superfamily, Member 9 - biosynthesis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Abstract SY09-01: Next-generation anti-CTLA-4 antibodies
by Korman, Alan J and Engelhardt, John and Loffredo, John and Valle, Jose and Akter, Rahima and Vuyyuru, Raja and Bezman, Natalie and So, Paula and Graziano, Robert and Tipton, Kimberly and West, James and Irving, Bryan and Selby, Mark
Cancer Research, ISSN 0008-5472, 07/2017, Volume 77, Issue 13 Supplement, pp. SY09-01 - SY09-01
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Erratum to FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis [Cancer Cell 28, 285-295; September 14, 2015]
by Dahan, Rony and Sega, Emanuela and Engelhardt, John and Selby, Mark and Korman, Alan J and Ravetch, Jeffrey V
Cancer Cell, ISSN 1535-6108, 10/2015, Volume 28, Issue 4, p. 543
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Fc[gamma]Rs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis
by Dahan, Rony and Sega, Emanuela and Engelhardt, John and Selby, Mark and Korman, Alan J and Ravetch, Jeffrey V
Cancer Cell, ISSN 1535-6108, 10/2015, Volume 28, Issue 4, p. 543
Viral antibodies | Antibodies | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Fc[gamma]Rs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis
by Dahan, Rony and Sega, Emanuela and Engelhardt, John and Selby, Mark and Korman, Alan J and Ravetch, Jeffrey V
Cancer Cell, ISSN 1535-6108, 09/2015, Volume 28, Issue 3, p. 285
Immune checkpoint blockade of the programmed cell death protein 1 (PD-1) pathway by monoclonal antibodies (Abs) has shown promising clinical benefit in the... 
Monoclonal antibodies | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
by Gubin, Matthew M and Zhang, Xiuli and Schuster, Heiko and Caron, Etienne and Ward, Jeffrey P and Noguchi, Takuro and Ivanova, Yulia and Hundal, Jasreet and Arthur, Cora D and Krebber, Willem-Jan and Mulder, Gwenn E and Toebes, Mireille and Vesely, Matthew D and Lam, Samuel S.K and Korman, Alan J and Allison, James P and Freeman, Gordon J and Sharpe, Arlene H and Pearce, Erika L and Schumacher, Ton N and Aebersold, Ruedi and Rammensee, Hans-Georg and Melief, Cornelis J.M and Mardis, Elaine R and Gillanders, William E and Artyomov, Maxim N and Schreiber, Robert D
Nature, ISSN 0028-0836, 11/2014, Volume 515, Issue 7528, pp. 577 - 581
The immune system influences the fate of developing cancers by not only functioning as a tumour promoter that facilitates cellular transformation, promotes... 
IMMUNITY | RESPONSES | IMMUNOGENICITY | MELANOMA | QUANTITATIVE PROTEOMICS | INFLAMMATION | MULTIDISCIPLINARY SCIENCES | EQUILIBRIUM | PD-1 | EXOME ANALYSIS REVEALS | T-CELLS | Antigens, Neoplasm - genetics | Sarcoma - immunology | Antigens, Neoplasm - immunology | Antibodies, Monoclonal - therapeutic use | Male | Vaccines, Synthetic - therapeutic use | Epitopes - genetics | Sarcoma - therapy | Cancer Vaccines - therapeutic use | Animals | Immunotherapy | Mice | CD8-Positive T-Lymphocytes - immunology | Cell Cycle Checkpoints - immunology | Care and treatment | Sarcoma | Analysis | Development and progression | Drug therapy | Health aspects | Antigenic determinants | Cancer | Antigens | Peptides | Lymphocytes | Mutation | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective Fc[gamma]R Engagement
by Dahan, Rony and Barnhart, Bryan C and Li, Fubin and Yamniuk, Aaron P and Korman, Alan J and Ravetch, Jeffrey V
Cancer Cell, ISSN 1535-6108, 06/2016, Volume 29, Issue 6, p. 820
While engagement of the inhibitory Fc[gamma]-receptor (Fc[gamma]R) IIB is an absolute requirement for in vivo antitumor activity of agonistic mouse anti-CD40... 
Analysis | Monoclonal antibodies | Health aspects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Evolving synergistic combinations of targeted immunotherapies to combat cancer
by Melero, Ignacio and Berman, David M and Aznar, M. Angela and Korman, Alan J and Gracia, José Luis Pérez and Haanen, John
Nature Reviews Cancer, ISSN 1474-175X, 08/2015, Volume 15, Issue 8, pp. 457 - 472
Immunotherapy has now been clinically validated as an effective treatment for many cancers. There is tremendous potential for synergistic combinations of... 
IMMUNOSTIMULATORY MONOCLONAL-ANTIBODIES | TUMOR-INFILTRATING LYMPHOCYTES | METASTATIC MELANOMA | CTLA-4 BLOCKADE | ANTI-GITR MAB | ONCOLOGY | RANDOMIZED CLINICAL-TRIAL | IN-VIVO | REGULATORY T-CELLS | CHRONIC VIRAL-INFECTION | FC-GAMMA-RIIB | Tumor Microenvironment - immunology | Neoplasms - therapy | Animals | Neoplasms - immunology | Humans | Immunotherapy | Biomarkers, Tumor - metabolism | Antineoplastic Agents - pharmacology | Antineoplastic Agents - therapeutic use | Clinical Trials as Topic | Combined Modality Therapy | Molecular Targeted Therapy | Care and treatment | Pharmacology, Experimental | Oncology, Experimental | Innovations | Drug targeting | Research | Methods | Drug synergism | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
by Topalian, Suzanne L and Hodi, F. Stephen and Brahmer, Julie R and Gettinger, Scott N and Smith, David C and McDermott, David F and Powderly, John D and Carvajal, Richard D and Sosman, Jeffrey A and Atkins, Michael B and Leming, Philip D and Spigel, David R and Antonia, Scott J and Horn, Leora and Drake, Charles G and Pardoll, Drew M and Chen, Lieping and Sharfman, William H and Anders, Robert A and Taube, Janis M and McMiller, Tracee L and Xu, Haiying and Korman, Alan J and Jure-Kunkel, Maria and Agrawal, Shruti and McDonald, Daniel and Kollia, Georgia D and Gupta, Ashok and Wigginton, Jon M and Sznol, Mario
The New England Journal of Medicine, ISSN 0028-4793, 06/2012, Volume 366, Issue 26, pp. 2443 - 2454
Releasing T cells from inhibitory control has been a strategy exploited by the anti–CTLA-4 antibody ipilimumab. Now an antibody against a second checkpoint... 
CELL LUNG-CANCER | MEDICINE, GENERAL & INTERNAL | THERAPY | SOLID TUMORS | RESPONSE CRITERIA | IMMUNOTHERAPY | GUIDELINES | B7 FAMILY | B7-H1 | ANTITUMOR IMMUNITY | BLOCKADE | Neoplasms - metabolism | Antibodies, Monoclonal - pharmacology | Humans | Antibodies, Monoclonal - adverse effects | Programmed Cell Death 1 Receptor - metabolism | Antibodies, Monoclonal - therapeutic use | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Neoplasms - drug therapy | Dose-Response Relationship, Drug | Antineoplastic Agents - adverse effects | Colorectal Neoplasms - drug therapy | Melanoma - drug therapy | Adult | Female | Ligands | Antineoplastic Agents - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Programmed Cell Death 1 Receptor - immunology | Carcinoma, Renal Cell - drug therapy | Prostatic Neoplasms - drug therapy | Drugs | Dose-response relationship (Biochemistry) | Immune response | Anti-antibodies | Dosage and administration | Product/Service Evaluations | Regulation | Research | Drug therapy | Cancer | Fees & charges | Kidneys | Stock options | PD-1 protein | Laboratories | Toxicity | Tumor cells | Body weight | Lung cancer | Colorectal carcinoma | Colorectal cancer | Melanoma | Licenses | Lymphocytes T | Patients | Castration | PD-L1 protein | Antitumor activity | Prostate cancer | Drug dosages | Prostate | Clear cell-type renal cell carcinoma | Tumors | Apoptosis | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis
by Dahan, Rony and Sega, Emanuela and Engelhardt, John and Selby, Mark and Korman, Alan J and Ravetch, Jeffrey V
Cancer Cell, ISSN 1535-6108, 09/2015, Volume 28, Issue 3, pp. 285 - 295
Immune checkpoint blockade of the programmed cell death protein 1 (PD-1) pathway by monoclonal antibodies (Abs) has shown promising clinical benefit in the... 
CELLS | ANTI-PD-L1 ANTIBODY | EFFICACY | ONCOLOGY | SAFETY | PD-1 BLOCKADE | TUMOR-ASSOCIATED MACROPHAGES | DEPLETION | REGULATORY T | CANCER | RECEPTOR ENGAGEMENT DRIVES | CELL BIOLOGY | Tumor Microenvironment - immunology | Animals | Neoplasms - immunology | Antibodies - immunology | Cell Line, Tumor | Ligands | Mice | Programmed Cell Death 1 Receptor - immunology | Receptors, IgG - immunology | B7-H1 Antigen - immunology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights